


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+4.15%
-10.04%
+13.13%
NVAX
Novavax
$9.75
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive
NVAX Price Performance
$6.79 (+43.59%)
$8.7 (+12.07%)
$7.58 (+28.63%)
$8.27 (+17.90%)
NVAX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Loss widens YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
NVAX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVAX Street Sentiment is extremely bullish and have negative views on the near-term outlook
NVAX has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
NVAX
Novavax
9.75
-1.66%
EHGO
Eshallgo Inc.
0.24
+2.17%
NBTX
Nanobiotix S.A. American
21.19
+5.63%
KMB
Kimberly-Clark
102.19
+2.17%
APRE
Aprea Therapeutics
0.84
+1.19%
What is NVAX current stock price?
What are NVAX stock strengths?
What is NVAX Risk Level?
What is NVAX market cap and volume?
What is NVAX current Stock IQ?
Should I buy NVAX stock right now?
Is NVAX a Strong Buy right now?
What does a 'Strong Buy' rating mean for NVAX?
What does a 'Strong Sell' rating mean for NVAX?
What factors influence NVAX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.15%
-10.04%
+13.13%
NVAX
Novavax
Current Price
$9.75
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Investors confidence is positive
Recently Viewed
NVAX
Novavax
9.75
-1.66%
EHGO
Eshallgo Inc.
0.24
+2.17%
NBTX
Nanobiotix S.A. American
21.19
+5.63%
KMB
Kimberly-Clark
102.19
+2.17%
APRE
Aprea Therapeutics
0.84
+1.19%

NVAX Price Performance
$6.79 (+43.59%)
$8.7 (+12.07%)
$7.58 (+28.63%)
$8.27 (+17.90%)
NVAX Analysts Opinion
NVAX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Loss widens YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow
![]()
NVAX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
NVAX Street Sentiment is extremely bullish and have negative views on the near-term outlook
NVAX has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Nov 05, 2025
Reiterate
Hold
TD Cowen
Oct 25, 2025
Initiate
Overweight
Cantor Fitzgerald
Oct 24, 2025
Reiterate
Buy
HC Wainwright & Co.
NVAX Stock IQ
NVAX Latest Analysis
Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln . (RTTNews) - Novavax Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer Inc. (PFE) for use of Novavaxs Matrix-M adjuvant. Under the terms of the agreement Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizers products
Tue Jan 20, 2026
Novavax Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference.
Thu Jan 15, 2026
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?. Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wed Jan 14, 2026
CORRECTED: Why Is Novavax Stock Soaring?. Editor’.s Note: This article has been updated to correct stock price action. ) .Novavax stock is among today’.s top performers. The CDC said on Friday Jan. 9 2026 that respiratory illness activity remains high nationwide. Flu cases are elevated and expected to stay that way for several more weeks. RSV levels are also high in many regions with emergency room visits and hospitalizations increasing among children ages 0–4. COVID‑19 activity is sti
Tue Jan 13, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
NVAX Stock trends
NVAX Stock performance
NVAX Stock analysis
NVAX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.